Search Results - "David, Hudesman"

Disease monitoring in inflammatory bowel disease by Chang, Shannon, Malter, Lisa, Hudesman, David

“…The optimal method for monitoring quiescent disease in patients with Crohn’s disease(CD) and ulcerative colitis is yet to be determined. Endoscopic evaluation…”
Get full text

Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease by Lee, June-Yong, Hall, Jason A., Kroehling, Lina, Wu, Lin, Najar, Tariq, Nguyen, Henry H., Lin, Woan-Yu, Yeung, Stephen T., Silva, Hernandez Moura, Li, Dayi, Hine, Ashley, Loke, P’ng, Hudesman, David, Martin, Jerome C., Kenigsberg, Ephraim, Merad, Miriam, Khanna, Kamal M., Littman, Dan R.

“…Lymphoid cells that produce interleukin (IL)-17 cytokines protect barrier tissues from pathogenic microbes but are also prominent effectors of inflammation and…”
Get full text

Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy by Hong, Simon J, Zenger, Cameron, Pecoriello, Jillian, Pang, Alice, Vallely, Margaret, Hudesman, David P, Chang, Shannon, Axelrad, Jordan E

“…There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are…”
Get full text

From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area by Axelrad, Jordan E, Malter, Lisa, Hong, Simon, Chang, Shannon, Bosworth, Brian, Hudesman, David

“…Abstract Background We aimed to characterize patients with inflammatory bowel disease (IBD) and novel coronavirus disease 2019 (COVID-19). Methods We performed…”
Get full text

A Joint Effort: Improving the Identification of Spondyloarthritis in Patients With Inflammatory Bowel Disease by Hong, Simon J, Hudesman, David P, Scher, Jose U

Get full text

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium by Dulai, Parambir S, Singh, Siddharth, Jiang, Xiaoqian, Peerani, Farhad, Narula, Neeraj, Chaudrey, Khadija, Whitehead, Diana, Hudesman, David, Lukin, Dana, Swaminath, Arun, Shmidt, Eugenia, Wang, Shuang, Boland, Brigid S, Chang, John T, Kane, Sunanda, Siegel, Corey A, Loftus, Edward V, Sandborn, William J, Sands, Bruce E, Colombel, Jean-Frederic

“…We assessed the real-world effectiveness and safety of vedolizumab (VDZ) in moderate-severe Crohn's disease (CD). Retrospective cohort study of seven medical…”
Get full text

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program by Dubinsky, Marla C, Magro, Fernando, Steinwurz, Flavio, Hudesman, David P, Kinnucan, Jami A, Ungaro, Ryan C, Neurath, Markus F, Kulisek, Nicole, Paulissen, Jerome, Su, Chinyu, Ponce de Leon, Dario, Regueiro, Miguel

“…Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). These post hoc analyses assessed associations between…”
Get full text

Implementation of an Inpatient IBD Service Is Associated with Improvement in Quality of Care and Long-Term Outcomes by Hong, Simon J., Jang, Janice, Berg, Dana, Kirat, Tarik, Remzi, Feza, Chang, Shannon, Malter, Lisa B., Axelrad, Jordan E., Hudesman, David P.

“…Background There is wide variation in the quality of care of hospitalized patients with inflammatory bowel disease (IBD). Prior studies have demonstrated that…”
Get full text

Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection by Axelrad, Jordan E, Li, Terry, Bachour, Salam P, Nakamura, Takahiro I, Shah, Ravi, Sachs, Michael C, Chang, Shannon, Hudesman, David P, Holubar, Stefan D, Lightner, Amy L, Barnes, Edward L, Cohen, Benjamin L, Rieder, Florian, Esen, Eren, Remzi, Feza, Regueiro, Miguel, Click, Benjamin

“…Abstract Background Postoperative recurrence (POR) of Crohn’s disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for…”
Get full text

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study by David, Hudesman, Millie, Long, Douglas, Wolf, Stephen, Hanauer, Subrata, Ghosh, AnnKatrin, Petersen, Marc, Pondel, Michael, Silver, Raymond, Cross, Brian, Feagan

“…True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with once-daily…”
Get full text

Receptive Anal Intercourse in Patients with Inflammatory Bowel Disease: A Clinical Review by Martin, Tracey, Smukalla, Scott M, Kane, Sunanda, Hudesman, David P, Greene, Richard, Malter, Lisa B

“…Receptive anal intercourse and its association with sexually transmitted infections and human papillomavirus-related anal dysplasia has been well studied in…”
Get full text

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease by Pineles, David, Malter, Lisa, Liang, Peter S., Arsuaga, Amy, Bosworth, Brian, Hudesman, David P., Chang, Shannon

Get full text

P039 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Crohn’s Disease in Remission by David, Hudesman, Jenny, Sauk, Joe, Zhuo, Ryan, Harrison, Samantha, Kerti, Kelechi, Emeanuru, Harris, Ahmad, Antoine, Sreih, Joehl, Nguyen, Raymond, Cross, Sara, Horst

“…In this analysis, we investigated differences in enrollment characteristics between CD patients in remission reporting impaired PROs vs those without…”
Get full text

P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission by Sara, Horst, David, Hudesman, Joe, Zhuo, Ryan, Harrison, Samantha, Kerti, Kelechi, Emeanuru, Harris, Ahmad, Antoine, Sreih, Joehl, Nguyen, Raymond, Cross, Jenny, Sauk

“…Analysis included patients enrolled in the Corrona IBD Registry from May 3, 2017 through September 3, 2019 with a diagnosis of UC who were in remission…”
Get full text

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile by Lukin, Dana J, Lawlor, Garrett, Hudesman, David P, Durbin, Laura, Axelrad, Jordan E, Passi, Monica, Cavaliere, Kimberly, Coburn, Elliot, Loftus, Michelle, Jen, Henry, Feathers, Alexandra, Rosen, Melissa H, Malter, Lisa B, Swaminath, Arun

“…Abstract Background Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion…”
Get full text

Capsule endoscopy in Crohn’s disease: Are we seeing any better? by Hudesman, David, Mazurek, Jonathan, Swaminath, Arun

“…Crohn’s disease(CD) is a complex, immune-mediated disorder that often requires a multi-modality approach for optimal diagnosis and management. While…”
Get full text

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States by Hong, Simon J, Krugliak Cleveland, Noa, Akiyama, Shintaro, Zullow, Samantha, Yi, Yangtian, Shaffer, Seth R, Malter, Lisa B, Axelrad, Jordan E, Chang, Shannon, Hudesman, David P, Rubin, David T

“…Ustekinumab has been recently approved for the treatment of moderately to severely active ulcerative colitis (UC). The registry trials for ustekinumab in UC…”
Get full text

Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program by Hudesman, David P., Torres, Joana, Salese, Leonardo, Woolcott, John C., Mundayat, Rajiv, Su, Chinyu, Mosli, Mahmoud H., Allegretti, Jessica R.

“…Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The tofacitinib OCTAVE clinical program…”
Get full text

COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study by Hong, Simon J., Bhattacharya, Sumona, Aboubakr, Aiya, Nadkarni, Devika, Lech, Diana, Ungaro, Ryan C., Agrawal, Manasi, Hirten, Robert P., Greywoode, Ruby, Mone, Anjali, Chang, Shannon, Hudesman, David P., Ullman, Thomas, Sultan, Keith, Lukin, Dana J., Colombel, Jean-Frederic, Axelrad, Jordan E.

“…Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the…”
Get full text

Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study by Hudesman, David P, Chakravarty, Soumya D, Emond, Bruno, Ellis, Lorie A, Lefebvre, Patrick, Sadik, Kay, Scher, Jose U

“…Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory…”
Get full text